Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 18/20 | 0.81 |
| ▸ | MAPK9 | P45984 | 18/20 | 0.81 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.81 |
| ▸ | CDK7 | P50613 | 1/20 | 0.58 |
| ▸ | CCNH | P51946 | 1/20 | 0.58 |
| ▸ | PIKFYVE | Q9Y2I7 | 2/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14979763 | 0.89 | MAPK8 (1.00) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL29403524 | 0.89 | MAPK8 (1.00) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL23924257 | 0.89 | MAPK8 (1.00) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL16171333 | 0.88 | MAPK8 (0.66) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL16171316 | 0.82 | MAPK8 (0.77) | MAPK8MAPK9MAPK10IRAK1 | |
| SCHEMBL14979771 | 0.79 | MAPK8 (0.77) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL23870567 | 0.78 | MAPK8 (0.78) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL3442630 | 0.77 | MAPK8 (0.68) | MAPK8MAPK9MAPK10SLC2A1 | |
| SCHEMBL3442508 | 0.76 | MAPK8 (0.66) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL16171315 | 0.75 | MAPK8 (0.80) | MAPK8MAPK9MAPK10IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368910-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-9382239-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140309249-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | Dana-Farber Cancer Intitute, Inc. (US) | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368910-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | MAPK8 52/4885MAPK9 34/4885MAPK10 44/4885 |
| US-20140309249-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | MAPK8 52/4885MAPK9 34/4885MAPK10 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.